Microdose Psychedelic Insights

The FDA panel has rejected the first MDMA treatment for PTSD, citing serious concerns about the quality and reliability of the clinical trials conducted: https://lnkd.in/embusYv3

We recently sat down with Sam Clark, MD PhD, CEO of Terran Biosciences, to discuss the exciting developments in their pipeline, particularly their latest schizophrenia therapeutic, TerXT, along with the development of new forms of psilocybin, MDMA, and 5-MeO-DMT. This novel therapeutic offers both a once-daily pill and a multi-month injection, designed to improve medication adherence and patient outcomes. Terran is planning to move forward with Phase I pharmacokinetic studies after the pending approval of KarXT. Learn more by reading the full interview now https://lnkd.in/g8RAdQ3A

Check out the latest article from Microdose Psychedelic Insights titled "Harnessing Ketamine for Complex Psychiatric Cases: A Dual Diagnosis Approach," the article explores our groundbreaking case study featured in Frontiers in Psychiatry, illustrating the promising outcomes observed in a patient with comorbid bipolar disorder and ASD who underwent treatment at our flagship clinic in Knoxville, Tennessee. This illuminating case study delves into the unique therapeutic journey of a 29-year-old male, offering insights into his struggles with mood swings, suicidal ideation, and challenges associated with ASD. Despite minimal relief from conventional medications, the patient experienced notable improvements in symptoms following a series of ketamine infusions, highlighting the potential of KAP as a dual therapeutic agent for both mood and neurodevelopmental disorders. The case report not only underscores the innovative approach of KAP but also emphasizes the importance of multidisciplinary collaboration in addressing complex psychiatric conditions. With a commitment to pioneering treatments that enhance mental health and overall well-being, Revitalist remains at the forefront of psychiatric care, pushing the boundaries of possibility and offering hope to those in need. Stay tuned as we continue to explore the transformative power of KAP and other innovative therapies in revolutionizing mental health treatment. Link in Comments! #Revitalist #KetamineTherapy #MentalHealthAwareness Kathryn Walker

The impact of under-representation of women in clinical trials is significant and has resulted in an over-representation of serious adverse events and side effects from prescribed medications in women. Tune into Dr Rachael Sumner, who discusses the issues and the team's approach in newly approved clinical trials for negative mood symptom alleviation in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Imagine embarking on a psychedelic journey as stepping into a portal to self-discovery and healing. It's an intense and profound experience that can open new doors of perception and bring forth deep insights. However, once the journey ends, the real work begins. Integration and aftercare are like the nurturing soil that allows those seeds of transformation to take root and flourish. Psychedelic integration can take many forms, but it typically involves talking to a therapist or counselor about the experience, journaling about it, and making lifestyle changes to support the new insights and perspectives gained during the psychedelic experience. Read the full article to learn more.

MindBio Therapeutics has announced groundbreaking results from a Phase 2a clinical trial involving the take-home microdosing of MB22001 for treating depression. This world-first trial showcased a significant decrease in depression symptoms over 8 weeks, with a 60% reduction in depressive symptoms and 53% of patients achieving complete remission. The trial achieved its primary efficacy endpoint with an average 14.1 point drop in the Montgomery-Asberg Depression Rating Scale (MADRS), demonstrating the safe and effective use of MB22001 in a take-home setting without any serious treatment-related adverse events. This marks a pivotal moment for MindBio as it progresses into late-stage pharmaceutical drug development, emphasizing the potential of MB22001, a self-titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home use, in treating depression. https://lnkd.in/epyz7VVq

We have some wonderful news to share! The interim top line results from MindBio Therapeutic's (CNSX: MBIO) Phase 2a Microdosing Depression trial are in and the results are astounding. 🔥 Astonishingly, over half the patients entering the trial with clinically diagnosed Major Depressive Disorder are in complete remission from their depression at week 8. 🎆 The primary efficacy endpoint was achieved with an impressive mean 14.1 point drop in Montgomery Asberg Depression Rating Scale score, representing a 60% reduction in depressive symptoms. I must admit, the scale of the improvements in depressive symptoms even surprised me as we advance this novel medicine through late-stage clinical trials. We're targeting Major Depressive Disorder and related conditions with MB22001. 🎓 A patient can self-administer MB22001 in titratable microdoses at home and then get on with their day and it’s exactly what we have been testing with regulatory support in clinical trials in the real world. Microdosing MB22001 for Depression is a revolutionary approach to the potential scalable and affordable use of these types of medicines as a first line treatment for Depression. Stay tuned for further developments and Stay Well!

In a new study, researchers including Tommaso Barba from the Centre for Psychedelic Research at Imperial College London found that on average, people reported improvements across a range of areas of sexual function up to six months after their psychedelic experience, including their enjoyment of sex, sexual arousal, satisfaction with sex, attraction to partner, their own physical appearance, communication, and their sense of connection. https://lnkd.in/gDWDMh8G

Do you know anyone who can benefit from the FREE TRIAL we have starting soon? THURSDAY February 1st at 5:30pm EST, we will be holding an info session about ketamine-assisted therapy + trauma informed yoga. We will discuss the trial itself and qualifications. Please join us if you believe you may qualify and can benefit (or share with anyone you know who could) from this trial. ***This event has been changed from in person to online so that more may attend***

Join clinician Cannectd Shari B Kaplan, LCSW, for a two day Integrative Mental Health Intensive Workshop providing an in depth approach of best practices for integrative mental health. Kaplan will educate on her integrative approach from assessments, treatment plans and process. 🎟 Tickets: https://lnkd.in/e8Bw_BHF 📍 Boca Raton, FL 33432, USA. 👨⚕️ 👩⚕️ Who is it for: The workshop is designed for clinicians, therapists, social workers, MFTs, nurses, psychologists, and other mental health professionals looking to incorporate integrative techniques into mental health treatment plans.